Early survival rate of uterine leiomyosarcoma

The early survival rate of uterine leiomyosarcoma is usually higher, and the 5-year survival rate can reach 70%-90%. Survival rate is closely related to factors such as tumor stage, degree of differentiation, and treatment regimen.

Uterine leiomyosarcoma is a common type of uterine sarcoma. Early stage patients usually refer to the stage when the tumor is limited to the uterine body without distant metastasis. Early-stage patients can obtain a better prognosis through standardized treatment. Surgical resection is the main treatment method. Complete removal of tumor tissue is crucial to improving survival rate. Postoperative adjuvant radiotherapy or chemotherapy may be required based on the pathological results to help reduce the risk of recurrence. Regular follow-up examinations play an important role in monitoring changes in the condition. It is recommended to conduct a pelvic examination and imaging evaluation every 3-6 months in the first two years after surgery.

Although the overall prognosis of early-stage patients is better, some cases may still experience recurrence or metastasis. Pathological features such as larger tumor size, active mitotic figures, and presence of vascular invasion may indicate a relatively poor prognosis. Recurrence often occurs within 2-3 years after surgery, and the lungs are the most common site of distant metastasis. Comprehensive methods such as reoperation, targeted therapy, or immunotherapy can be used for patients with recurrence, and some cases can still achieve long-term survival.

Maintaining a regular schedule and a balanced diet can help with postoperative recovery, and proper supplementation of high-quality protein and vitamins can promote tissue repair. Avoid overexertion and mood swings, follow the doctor's instructions for regular review and complete follow-up treatment. If symptoms such as abnormal vaginal bleeding and pelvic pain occur, you should seek medical examination promptly.